Anti Amyloid Leqembi denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for anti amyloid leqembi are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Leqembi as "Experimental" — and Why That Classification Is Contestable

Leqembi (lecanemab) received traditional FDA approval for early Alzheimer's disease. A denial categorizing an FDA-approved drug as "experimental" or "investigational" is one of the most aggressively appealable denial types because it contradicts the regulatory record. Aetna may be relying on a coverage policy that has not been updated since the traditional approval, or applying an internal evidence threshold that exceeds the FDA standard — both of which are legally and clinically challengeable.

## Why This Denial Happens

Insurers sometimes maintain internal evidence-review criteria that classify a drug as experimental even after FDA approval, arguing that long-term real-world data is insufficient or that the clinical evidence base does not meet the plan's own standards. While plans have some latitude to set evidence thresholds, those thresholds cannot be applied arbitrarily, and a denial that ignores FDA approval status is a strong candidate for reversal on appeal — especially by an independent reviewer.

## Federal Appeal Rights

• Internal appeal (ACA §2719 / ERISA §503): Submit a written appeal within the timeframe on the denial notice. The full-and-fair review standard requires Aetna to engage with the clinical evidence you submit, not simply re-apply the same coverage policy.
• Expedited review: If delay poses a serious health risk, your neurologist can certify the need for expedited review (72-hour response).
• External review: This denial type is particularly well-suited for external review. IROs are required to apply generally accepted standards of medical practice — not individual plan evidence criteria — when determining whether a treatment is experimental. The four-month window to request external review begins at the final internal denial. IRO decisions are binding on Aetna.
• State law protections: Many states prohibit plans from classifying FDA-approved drugs as experimental. Check whether your state's insurance code or managed-care statute applies to your plan.

## Documentation to Gather

1. FDA approval documentation — The current FDA prescribing label and the FDA approval letter, confirming traditional (not accelerated) approval status and the approved indication. 2. Guideline organization endorsement — Ask your neurologist to reference whether the applicable specialty society guideline (e.g., from the relevant neurology or dementia guideline body) addresses Leqembi. You do not need to quote statistics — the existence of a guideline recommendation is itself evidence against an experimental classification. 3. Diagnosis and eligibility records — Clinical notes confirming early symptomatic Alzheimer's disease and amyloid confirmation consistent with the FDA-approved indication. 4. Aetna's clinical policy — Obtain the specific policy Aetna cited. Identify whether it was updated after the traditional FDA approval date. A policy last revised before the approval date is a procedural vulnerability. 5. Prescriber medical-necessity letter — A letter from the neurologist stating that Leqembi is the standard of care for this patient's confirmed diagnosis and is not experimental.

## Criteria-Mapping Structure for Your Appeal

| Aetna's Experimental Basis | Your Response | Evidence | |---|---|---| | FDA approval status | Traditional approval confirmed | FDA label + approval letter | | Plan's evidence threshold | Exceeds FDA standard | Policy version date vs. approval date | | Guideline support | Specialty society position | Neurologist letter referencing applicable guideline | | Applicable indication met | Patient meets approved indication | Diagnosis records + amyloid confirmation |